Our Programs

Epigenetics Program

DRUG CANDIDATE

Pracinostat HDAC Inhibitor

INDICATION / COMBINATION

Acute Myeloid Leukemia

Newly diagnosed, unfit for intensive chemotherapy
Azacitidine (Vidaza®)
Pre-Clinical
Phase I
Phase II
Phase III
 
INDICATION / COMBINATION

Myelodysplastic Syndrome

High & very high risk
Azacitidine (Vidaza®)
Pre-Clinical
Phase I
Phase II
Phase III
 
INDICATION / COMBINATION

Myelofibrosis

Front line & relapsed/refractory
Ruxolitinib (Jakafi®)
Pre-Clinical
Phase I
Phase II
Phase III
 

Signaling Program

DRUG CANDIDATE

ME-401 PI3K Delta Inhibitor

INDICATION / COMBINATION

CLL & Follicular Lymphoma

Relapsed/Refractory
Single Agent
Pre-Clinical
Phase I
Phase II
Phase III
 

Cancer Metabolism Program

DRUG CANDIDATE

ME-344 Mitochondrial Inhibitor

INDICATION / COMBINATION

HER2-Negative Breast

Treatment-naïve, early stage
Bevacizumab (Avastin)
Pre-Clinical
Phase I
Phase II
Phase III